Publication November 13, 2026

Publication on AS01(E)-Adjuvanted RSV Vaccine in Transplant Patients

A new publication dated November 13, 2026 reports results from a phase 2b randomized trial titled "AS01(E)-adjuvanted RSV pre-F protein vaccine in adults with lung or kidney transplant: a phase 2b randomized trial." The study was published in Nature Communications. The trial examined an RSV pre-F protein vaccine formulated with the AS01(E) adjuvant, studied in adults who had received either a lung or kidney transplant. This entry reflects only that the publication exists, naming its title, journal, and date. No findings, outcomes, or safety data from the trial are included here beyond the title itself. Readers interested in the specific results, methodology, or conclusions should consult the published article directly through the source link provided. This brief does not characterize efficacy or risk associated with the vaccine candidate described in the trial. For general background on GHK and its compound profile, readers can consult the compound overview page.

See the full ghk overview

Source: https://pubmed.ncbi.nlm.nih.gov/43026212/